UniQure Expects Quick Approval Of Gene Therapy Used For Hemophilia B.

Reuters (2/8, Mishra) reports that “gene therapy company UniQure NV said on Friday its treatment for hemophilia B increased the levels of a protein that helps in blood clotting after 12 weeks in a relatively small study.” As a result, the company said it...